Monoclonal antibodies: versatile platforms for cancer immunotherapy. - Wikidata - wikimedia - TriplyDB

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

http://www.wikidata.org/entity/Q34111693

about

Antibody therapies for lymphoma in children Antibody therapies for lymphoma in children Targeting microRNAs as key modulators of tumor immune response Bacteria in Cancer Therapy: Renaissance of an Old Concept Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment Recent advances in the field of anti-cancer immunotherapy Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis Challenges in Antibody Development against Tn and Sialyl-Tn Antigens Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies Immunotherapy for prostate cancer: recent developments and future challenges Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response Molecular mechanisms of T cell co-stimulation and co-inhibition Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges Antibody-based immunotherapy for ovarian cancer: where are we at?Novel immunotherapies for hematologic malignancies A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics CD4 T-cell immunotherapy for chronic viral infections and cancer Monoclonal antibodies for the treatment of cancer Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target In vivo binding and retention of CD4-specific DARPin 57.2 in macaques Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies Cell labeling approaches for fluorescence-based in vivo flow cytometry Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Antibodies and antibody-derived analytical biosensors IgE immunotherapy against cancer Mechanisms of action of therapeutic antibodies for cancer Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc Glycoforms Pepsin-Containing Membranes for Controlled Monoclonal Antibody Digestion Prior to Mass Spectrometry Analysis.Bioconjugation of therapeutic proteins and enzymes using the expanded set of genetically encoded amino acids.Passive immunization against HIV/AIDS by antibody gene transfer.

P2860

Q24186437-C8085C05-5355-418E-AF7B-B693F8E5A07A Q24195106-B442B9B9-79D1-4BEC-A29B-E38B6620BC4A Q26746972-409BA0B2-8717-4C06-A4E2-558B830651FB Q26751222-5680DA8B-68A1-415B-9B0C-80FB6C9DAC58 Q26766718-3F5A7458-AF48-4FF4-BC31-418B130B35BD Q26769884-5E2DC4E6-CC7F-447F-AF9D-537C17669169 Q26769963-303B0954-8119-42EE-9B23-DFC859051337 Q26775602-C66D7E24-2A7A-4B7B-AB29-B7ADFA08CA99 Q26787279-97BFBF18-C6FD-4014-A37E-A918CAF0EBAD Q26798183-4CDA1AEF-A081-441B-A2EC-7295BCAED457 Q26822421-E79EFF04-2DC8-46F0-9006-831E35C137F5 Q26824462-9D4B1EF8-18B8-4652-883F-FC1155E7A5E3 Q26851608-F5119B7A-4797-4F10-B71D-844C22226C1E Q26852366-9870ADD6-6F57-4B54-BBC0-FA72C81989A8 Q26852388-4D9489C7-9960-49C8-B001-1F53C883CEF9 Q26863081-890636F6-FE67-43BA-A189-60617735E701 Q26864888-50C7DA99-C34F-46F7-A989-CC2F873437F9 Q26993238-9912848B-36EA-43ED-AC52-04C65C661C87 Q26995399-16B74E1A-971D-45C7-962B-6E9AEF5D3112 Q27000514-A8EC88A3-D84A-401B-8569-FE484680B6E7 Q27004436-C7B4E8F4-6E06-474B-93CC-F234718CE163 Q27006569-27D13D4D-A4BC-4D8D-AB74-76FDFE7D7D47 Q27022957-06CB8FB1-E394-4C42-AB58-2E1434ECB590 Q27025966-DBE5B2A0-8F2E-43BB-97E4-AFDD24F44529 Q27317164-E3AAE3B5-8459-457C-BD8D-B0AF91FEC51C Q27320871-0B2BE0CA-EE62-435C-8432-F99436F96ADE Q27345217-E26AF432-0055-4BF3-A23D-E19D172D74F4 Q27693903-446B0CD2-F8EB-4B9C-8EEC-F074B31FF934 Q27860857-760542DA-82D3-4988-9B29-5B014B5CA047 Q28068441-CB9EDC80-8500-4FB5-A8DF-C602CE6B7015 Q28081223-3EBE83A5-3544-4E7B-8AC8-477ED80DE753 Q28385366-268ABCA7-35F7-4FE1-9D4A-5770BDD1DDE3 Q28394869-0AB2457B-0972-4964-9617-CB47BB64A19D Q28487387-74C04DDE-FF5B-4453-94EA-A3464CC859EE Q28658712-5F81859E-0EFE-4762-95FD-5476E54C63F2 Q28740388-09E18BDF-892E-4E41-8459-C15809336942 Q28820826-4F90C08D-E084-4D8B-918B-944755CCDFDE Q30278544-956F4DF6-EE59-4B56-952E-37AADC54A9E0 Q30279245-0A5BEBAE-7807-4431-8821-87BE5B6231E1 Q30358434-02FF14A9-F10A-4E69-886A-87AA07AF1228

P2860

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

http://www.wikidata.org/entity/Q34111693

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@ast

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@en

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@nl

type

label

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@ast

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@en

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@nl

prefLabel

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@ast

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@en

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@nl

P1433

Q34111693-C30177F1-FCEC-438D-8F17-97DC912138D7

P1476

Q34111693-3F8F5D59-6612-473E-955B-E8523A5A546F

P2093

Q34111693-3458072A-4460-4684-A689-6B2B0B234238

Q34111693-9124ADAE-40D1-40EC-8E4F-755EE82B7C10

P2860

Q34111693-0B107DA0-BEA1-4119-B30F-9673FC5FDAC6

Q34111693-0D2FEEEC-A0C4-4DD6-A774-CB7C3A55D414

Q34111693-1541F7DD-DAAA-4EAE-A96F-D4559932B177

Q34111693-1B1D61C0-1151-4871-BBC8-DF4265926AD0

Q34111693-1B2F3E46-801C-4566-8B25-D3A30CFCBFC2

Q34111693-1B34B629-080E-4723-A15E-007A6FB21202

Q34111693-1BC9CC36-13F8-40DE-AD85-CB59686AA383

Q34111693-1E755787-D9FB-49CC-86F7-7D5E182C0669

Q34111693-1F313E8D-51BD-4895-A678-70C9B6831DB1

Q34111693-24A5A8C8-3DEB-49EC-8C83-5A28731632AC

P304

Q34111693-6C0561F8-14A1-46C3-8CD5-D31FE298536F

P31

Q34111693-2CFB961C-B6EC-4F54-A725-BFE5FE507DD4

P356

Q34111693-17C5A075-E78D-43E0-A85B-D40AAA84C871

P433

Q34111693-9EDDBCC2-8604-4BA7-8651-C6C8E0404922

P478

Q34111693-5ADB31B4-536C-4BA2-A18E-C9F3DE7D4F3F

P50

Q34111693-CCBD3D76-FC0F-4C00-BAA0-6684590F95CA

P577

Q34111693-8F67E62E-3BFD-4DC8-9F93-AB200000C5FF

P5875

Q34111693-99DCBA10-38F6-4908-8112-138DC5580EB2

P698

Q34111693-A8DAB4D8-0837-42E7-947E-D1AC7534C591

P921

Q34111693-36C340FA-3CB4-47D1-A576-9934F6ADF719

Q34111693-FFB42532-EC31-48C3-A4C6-2CC7042B91F5

P932

Q34111693-DFF535B3-4249-4983-873C-E2100B016482

P356

P1433

Nature Reviews Immunology

P1476

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

@en

P2093

Louis M Weiner

http://www.w3.org/2001/XMLSchema#string

Rishi Surana

http://www.w3.org/2001/XMLSchema#string

P2860

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

T helper 17 cells promote cytotoxic T cell activation in tumor immunity

PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate

Continuous cultures of fused cells secreting antibody of predefined specificity

A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

IL-23 promotes tumour incidence and growth

P304

317-327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRI2744

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43299747

http://www.w3.org/2001/XMLSchema#string

P698

20414205

http://www.w3.org/2001/XMLSchema#string

P921

P932

3508064

http://www.w3.org/2001/XMLSchema#string